NELSEN ROBERT — SEC insider filings

SEC reporting owner CIK 1219042. 91 insider filings on record with FilingPulse; latest filed 2026-11-05.

Transaction summary — filings shown

Covers the 50 most recent of 91 filings on record, filed 2022-08-26 to 2026-11-05. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.

By issuer — same filings

Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.

IssuerRole (as filed)FilingsPurchases (P)Sales (S)Other legs
Prime Medicine, Inc. (PRME)Director, 10% owner84 legs · 7,030,300 sh · $43,599,990—16
Metsera, Inc. (MTSR)Director, 10% owner22 legs · 2,222,222 sh · $39,999,996—9
Lyell Immunopharma, Inc. (LYEL)10% owner62 legs · 2,809,352 sh · $37,499,977—3
Neumora Therapeutics, Inc. (NMRA)10% owner920 legs · 3,922,764 sh · $36,430,001—12
Kardigan, Inc. (KARD)Director, 10% owner21 leg · 1,250,000 sh · $20,000,000—4
Aspen Neuroscience, Inc. (ASPE)10% owner23 legs · 1,333,333 sh · $19,999,995—18
Seaport Therapeutics, Inc. (SPTX)10% owner11 leg · 1,100,000 sh · $19,800,000—4
Sana Biotechnology, Inc. (SANA)Director, 10% owner83 legs · 1,818,181 sh · $9,999,996—7
Codiak BioSciences, Inc. (CDAK)10% owner11 leg · 5,000,000 sh · $7,500,000—1
Boundless Bio, Inc. (BOLD)10% owner22 legs · 200,000 sh · $3,200,0001 leg · 16,000 sh · $39,84012

+4 more issuers among the filings shown — every filing appears in the table below.

Insider filings — NELSEN ROBERT

FiledFormIssuerReported transactionsSource
2026-11-054Lyell Immunopharma, Inc. (LYEL)
jointly with ARCH Venture Fund XIII, L.P., ARCH Venture Partners XIII, L.P., ARCH Venture Partners XIII, LLC, CRANDELL KEITH, GILLIS STEVEN, Burow Kristina, BERNS PAUL L, BYBEE CLINTON
Purchase (P): 2,321,262 @ $10.77EDGAR
2026-11-024Aspen Neuroscience, Inc. (ASPE)
jointly with ARCH Venture Fund X, L.P., ARCH Venture Fund X Overage, L.P., ARCH Venture Partners X, L.P., ARCH Venture Partners X Overage, L.P., ARCH Venture Partners X, LLC, CRANDELL KEITH, Burow Kristina, GILLIS STEVEN
Purchase (P): 66,666 @ $15 · Conversion (C): 187,182 · Conversion (C): 298,258 · Conversion (C): 286,304 · Conversion (C): 295,490 · Conversion (C): 259,948 · +15 moreEDGAR
2026-10-293Aspen Neuroscience, Inc. (ASPE)
jointly with ARCH Venture Fund X, L.P., ARCH Venture Fund X Overage, L.P., ARCH Venture Partners X, L.P., ARCH Venture Partners X Overage, L.P., ARCH Venture Partners X, LLC, CRANDELL KEITH, Burow Kristina, GILLIS STEVEN
Holdings only — no transactions reportedEDGAR
2026-10-194CITY THERAPEUTICS, INC. (CTY)Conversion (C): 3,294,900 · Conversion (C): 5,482,309 · Conversion (C): 2,027,006 · Purchase (P): 170,000 @ $18 · Grant/award (A): 22,649 (derivative) @ $0 · Conversion (C): 3,000,000 (derivative) @ $0 · +2 moreEDGAR
2026-10-153CITY THERAPEUTICS, INC. (CTY)Holdings only — no transactions reportedEDGAR
2026-07-064Boundless Bio, Inc. (BOLD)
jointly with CRANDELL KEITH, BYBEE CLINTON, GILLIS STEVEN, Burow Kristina
Option exercise (M): 16,000 @ $1.03 · Sale (S): 16,000 @ $2.49 · Option exercise (M): 16,000 (derivative) @ $0EDGAR
2026-06-244Kardigan, Inc. (KARD)
jointly with ARCH Venture Partners XIII, LLC, ARCH Venture Partners XIII, L.P., ARCH Venture Fund XIII, L.P., CRANDELL KEITH, Burow Kristina, GILLIS STEVEN
Purchase (P): 1,250,000 @ $16EDGAR
2026-06-224Kardigan, Inc. (KARD)
jointly with ARCH Venture Partners XIII, LLC, ARCH Venture Partners XIII, L.P., ARCH Venture Fund XIII, L.P., CRANDELL KEITH, Burow Kristina, GILLIS STEVEN
Conversion (C): 13,792,035 · Conversion (C): 5,148,587 (derivative) · Conversion (C): 1,204,000 (derivative) · Conversion (C): 2,306,401 (derivative)EDGAR
2026-06-084Prime Medicine, Inc. (PRME)Grant/award (A): 75,000 (derivative) @ $0EDGAR
2026-06-054Sana Biotechnology, Inc. (SANA)Grant/award (A): 90,000 (derivative) @ $0EDGAR
2026-05-044Seaport Therapeutics, Inc. (SPTX)
jointly with ARCH Venture Partners XII, LLC, ARCH Venture Partners XII, L.P., ARCH Venture Fund XII, L.P., CRANDELL KEITH, Burow Kristina, GILLIS STEVEN
Conversion (C): 2,513,686 · Conversion (C): 2,681,265 · Purchase (P): 1,100,000 @ $18 · Conversion (C): 2,513,686 (derivative) @ $0 · Conversion (C): 2,681,265 (derivative) @ $0EDGAR
2026-03-094Lyell Immunopharma, Inc. (LYEL)
jointly with ARCH Venture Fund XIII, L.P., ARCH Venture Partners XIII, L.P., ARCH Venture Partners XIII, LLC, CRANDELL KEITH, Burow Kristina, GILLIS STEVEN, BERNS PAUL L, BYBEE CLINTON
Purchase (P): 488,090 @ $25.61EDGAR
2025-11-144Metsera, Inc. (MTSR)
jointly with ARCH Venture Partners XII, LLC, ARCH Venture Fund XII, L.P., ARCH Venture Partners XII, L.P., ARCH Venture Fund XIII, L.P., ARCH Venture Partners XIII, L.P., ARCH Venture Partners XIII, LLC, CRANDELL KEITH, GILLIS STEVEN
Disposition to issuer (D): 18,503,128 · Disposition to issuer (D): 8,313,680EDGAR
2025-10-294Neumora Therapeutics, Inc. (NMRA)
jointly with ARCH Venture Partners XII, LLC, ARCH Venture Partners XII, L.P., ARCH Venture Fund XII, L.P., CRANDELL KEITH, GILLIS STEVEN, BYBEE CLINTON
Purchase (P): 1,915,700 @ $2.61EDGAR
2025-08-054Prime Medicine, Inc. (PRME)Disposition to issuer (D): 39,062 (derivative) · Grant/award (A): 39,062 (derivative) · Disposition to issuer (D): 45,000 (derivative) · Grant/award (A): 45,000 (derivative)EDGAR
2025-08-014Prime Medicine, Inc. (PRME)Purchase (P): 3,030,300 @ $3.30EDGAR
2025-07-294Lyell Immunopharma, Inc. (LYEL)
jointly with ARCH Venture Partners IX, LLC, ARCH Venture Partners IX, L.P., ARCH Venture Partners IX Overage, L.P., ARCH Venture Fund IX, L.P., ARCH Venture Fund IX Overage, L.P., CRANDELL KEITH, BYBEE CLINTON
Holdings only — no transactions reportedEDGAR
2025-06-094Sana Biotechnology, Inc. (SANA)Grant/award (A): 80,000 (derivative) @ $0EDGAR
2025-06-054Prime Medicine, Inc. (PRME)Grant/award (A): 55,000 (derivative) @ $0EDGAR
2025-02-034Metsera, Inc. (MTSR)
jointly with ARCH Venture Partners XII, LLC, ARCH Venture Fund XII, L.P., ARCH Venture Partners XII, L.P., ARCH Venture Fund XIII, L.P., ARCH Venture Partners XIII, L.P., ARCH Venture Partners XIII, LLC, CRANDELL KEITH, GILLIS STEVEN
Conversion (C): 16,006,949 · Conversion (C): 7,523,682 · Purchase (P): 1,432,224 @ $18 · Purchase (P): 789,998 @ $18 · Conversion (C): 19,933,333 (derivative) · Conversion (C): 15,000,000 (derivative) · +3 moreEDGAR
2024-07-154/ASana Biotechnology, Inc. (SANA)Grant/award (A): 65,000 (derivative) @ $0EDGAR
2024-06-174Lyell Immunopharma, Inc. (LYEL)Grant/award (A): 130,000 (derivative) @ $0EDGAR
2024-06-144Prime Medicine, Inc. (PRME)Grant/award (A): 45,000 (derivative) @ $0EDGAR
2024-06-104Rapport Therapeutics, Inc. (RAPP)
jointly with ARCH Venture Partners XII, LLC, ARCH Venture Partners XII, L.P., ARCH Venture Fund XII, L.P., CRANDELL KEITH, Burow Kristina, GILLIS STEVEN
Conversion (C): 3,728,738 @ $0 · Conversion (C): 20,000,000 (derivative) @ $0 · Conversion (C): 11,924,138 (derivative) @ $0EDGAR
2024-06-074Sana Biotechnology, Inc. (SANA)Grant/award (A): 54,278 (derivative) @ $0EDGAR
2024-06-034Vir Biotechnology, Inc. (VIR)Grant/award (A): 8,000 @ $0 · Grant/award (A): 16,000 (derivative) @ $0EDGAR
2024-04-044Boundless Bio, Inc. (BOLD)
jointly with CRANDELL KEITH, BYBEE CLINTON, GILLIS STEVEN
Conversion (C): 589,743 · Conversion (C): 787,545 · Conversion (C): 1,048,433 · Purchase (P): 66,667 @ $16 · Purchase (P): 133,333 @ $16 · Conversion (C): 424,908 (derivative) · +6 moreEDGAR
2024-02-204Prime Medicine, Inc. (PRME)Purchase (P): 3,200,000 @ $6.25EDGAR
2024-02-124Sana Biotechnology, Inc. (SANA)Purchase (P): 363,637 @ $5.50 · Purchase (P): 727,272 @ $5.50 · Purchase (P): 727,272 @ $5.50EDGAR
2023-12-124Neumora Therapeutics, Inc. (NMRA)
jointly with ARCH Venture Partners XII, LLC, ARCH Venture Partners XII, L.P., ARCH Venture Fund XII, L.P., CRANDELL KEITH, GILLIS STEVEN, BYBEE CLINTON
Other (J): 703,061 · Other (J): 1,176,593EDGAR
2023-11-154Neumora Therapeutics, Inc. (NMRA)
jointly with ARCH Venture Partners XII, LLC, ARCH Venture Partners XII, L.P., ARCH Venture Fund XII, L.P., CRANDELL KEITH, GILLIS STEVEN
Purchase (P): 31,653 @ $11.75 · Purchase (P): 3,357 @ $11.98EDGAR
2023-11-134Neumora Therapeutics, Inc. (NMRA)
jointly with ARCH Venture Partners XII, LLC, ARCH Venture Partners XII, L.P., ARCH Venture Fund XII, L.P., CRANDELL KEITH, GILLIS STEVEN
Purchase (P): 69,127 @ $10.78 · Purchase (P): 23,124 @ $11.79 · Purchase (P): 31,079 @ $10.53 · Purchase (P): 11,844 @ $11.37 · Purchase (P): 5,431 @ $11.75EDGAR
2023-11-074Neumora Therapeutics, Inc. (NMRA)
jointly with ARCH Venture Partners XII, LLC, ARCH Venture Partners XII, L.P., ARCH Venture Fund XII, L.P., CRANDELL KEITH, GILLIS STEVEN
Purchase (P): 22,420 @ $11.38 · Purchase (P): 43,082 @ $11.55 · Purchase (P): 30,192 @ $11.50EDGAR
2023-09-294Neumora Therapeutics, Inc. (NMRA)
jointly with ARCH Venture Partners XII, LLC, ARCH Venture Partners XII, L.P., ARCH Venture Fund XII, L.P., CRANDELL KEITH, GILLIS STEVEN
Purchase (P): 16,841 @ $13.06 · Purchase (P): 25,110 @ $13.69 · Purchase (P): 34,560 @ $13.98EDGAR
2023-09-274Neumora Therapeutics, Inc. (NMRA)
jointly with ARCH Venture Partners XII, LLC, ARCH Venture Partners XII, L.P., ARCH Venture Fund XII, L.P., CRANDELL KEITH, GILLIS STEVEN
Purchase (P): 34,000 @ $11.73 · Purchase (P): 24,504 @ $12.31EDGAR
2023-09-254Neumora Therapeutics, Inc. (NMRA)
jointly with ARCH Venture Partners XII, LLC, ARCH Venture Partners XII, L.P., ARCH Venture Fund XII, L.P., CRANDELL KEITH, GILLIS STEVEN
Purchase (P): 40,000 @ $11.14 · Purchase (P): 30,773 @ $10.80 · Purchase (P): 29,967 @ $11.65EDGAR
2023-09-204Neumora Therapeutics, Inc. (NMRA)
jointly with ARCH Venture Partners X, LLC, ARCH Venture Partners XII, LLC, ARCH Venture Partners XII, L.P., ARCH Venture Fund XII, L.P., CRANDELL KEITH, GILLIS STEVEN, BYBEE CLINTON
Conversion (C): 684,167 · Conversion (C): 1,144,973 · Conversion (C): 6,895,021 · Conversion (C): 6,576,400 · Conversion (C): 2,124,143 · Purchase (P): 1,500,000 @ $17 · +5 moreEDGAR
2023-09-084Lyell Immunopharma, Inc. (LYEL)Grant/award (A): 55,000 (derivative) @ $0EDGAR
2023-08-104DA32 Life Science Tech Acquisition Corp. (DALS)
jointly with ARCH Venture Fund XI, L.P., ARCH Venture Partners XI, L.P., ARCH Venture Partners XI, LLC, Burow Kristina, GILLIS STEVEN
Other (J): 1,600,000EDGAR
2023-06-204Lyell Immunopharma, Inc. (LYEL)Grant/award (A): 65,000 (derivative) @ $0EDGAR
2023-06-164Prime Medicine, Inc. (PRME)Grant/award (A): 39,062 (derivative) @ $0EDGAR
2023-06-124Sana Biotechnology, Inc. (SANA)Grant/award (A): 65,000 (derivative) @ $0EDGAR
2023-05-244Vir Biotechnology, Inc. (VIR)Grant/award (A): 6,027 @ $0 · Grant/award (A): 12,054 (derivative) @ $0EDGAR
2023-01-064Sana Biotechnology, Inc. (SANA)Grant/award (A): 536 @ $0EDGAR
2022-10-264Prime Medicine, Inc. (PRME)Conversion (C): 5,728,297 · Conversion (C): 5,728,297 · Purchase (P): 400,000 @ $17 · Purchase (P): 400,000 @ $17 · Conversion (C): 16,080 · Conversion (C): 16,666,667 (derivative) @ $0 · +4 moreEDGAR
2022-10-064Sana Biotechnology, Inc. (SANA)Grant/award (A): 321 @ $0EDGAR
2022-09-154Codiak BioSciences, Inc. (CDAK)
jointly with ARCH Venture Fund VIII, L.P., ARCH Venture Fund VIII Overage, L.P., CRANDELL KEITH, BYBEE CLINTON, ARCH Venture Partners VIII, LLC, ARCH Venture Partners VIII, L.P.
Purchase (P): 5,000,000 @ $1.50 · Purchase (P): 5,000,000 (derivative)EDGAR
2022-09-074Vir Biotechnology, Inc. (VIR)Other (J): 196,003 @ $0 · Other (J): 253,997 @ $0 · Other (J): 24,737 @ $0 · Other (J): 1,508 @ $0 · Other (J): 239,559 @ $0 · Other (J): 310,441 @ $0 · +2 moreEDGAR
2022-09-014Vir Biotechnology, Inc. (VIR)Other (J): 217,781 @ $0 · Other (J): 282,219 @ $0 · Other (J): 27,489 @ $0 · Other (J): 1,684 @ $0 · Other (J): 217,781 @ $0 · Other (J): 282,219 @ $0 · +2 moreEDGAR
2022-08-264Vir Biotechnology, Inc. (VIR)Other (J): 217,781 @ $0 · Other (J): 282,219 @ $0 · Other (J): 27,489 @ $0 · Other (J): 1,684 @ $0 · Other (J): 217,781 @ $0 · Other (J): 282,219 @ $0 · +2 moreEDGAR

FilingPulse's Form 4 archive currently extends back to 2020-09-21 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.

Need this as JSON? GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1219042 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs